ulting in loss of antiviral efficacy.
Pazopanib: Use caution when administering velpatasvir with pazopanib. Taking these medications together may increase the plasma concentrations of velpatasvir and pazopanib, potentially resulting in adverse events. Pazopanib is a substrate of the drug transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP); velpatasvir is a P-gp and BCRP inhibitor. Pazopanib is also a weak inhibitor of the hepatic enzymes CYP3A4 and CYP2C8. Velpatasvir is a substrate of both enzymes.
Perampanel: Use caution when administering velpatasvir with perampanel. Taking these drugs together may decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 substrate; perampanel is a weak in vitro inducer of CYP3A4.
Perindopril; Amlodipine: Use caution when administering velpatasvir with amlodipine. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Amlodipine is a weak CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Phenobarbital: Avoid coadministration of sofosbuvir with inducers of P-glycoprotein (P-gp), such as phenobarbital. Taking these drugs together may decrease sofosbuvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Avoid coadministration of velpatasvir with inducers of P-glycoprotein (P-gp) and CYP3A4, such as phenobarbital. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a P-gp and CYP3A4 substrate.
Phentermine; Topiramate: Use caution when administering velpatasvir with topiramate. Taking these drugs together may decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 substrate; topiramate is a weak inducer of CYP3A4.
Phenytoin: Avoid coadministration of sofosbuvir with inducers of P-glycoprotein (P-gp), such as phenytoin. Taking these drugs together may decrease sofosbuvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Avoid coadministration of velpatasvir with inducers of P-glycoprotein (P-gp) and CYP3A4, such as phenytoin. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy.
Pioglitazone: Use caution when administering velpatasvir with pioglitazone. Taking these drugs together may decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is a CYP3A4 substrate; pioglitazone is a weak inducer of CYP3A4.
Pirfenidone: Use caution when administering velpatasvir with pirfenidone. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); pirfenidone is a weak inhibitor of P-gp. Pirfenidone is also a weak in vitro inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Posaconazole: Use caution when administering velpatasvir with posaconazole. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). In addition, pos |
